Table 2 Baseline characteristics of patients

Demoule 2016

NAVA

62

66 (61, 77)

47 (76)

n/a

n/a

235 (185, 265)

4 (2, 8)^*

6 (5, 8)

12 (10, 16)

Control

66

64 (53, 77)

39 (59)

n/a

n/a

227 (192, 286)

5 (3, 8)^*

6 (5, 8)

12 (10, 14)

Kuo 2016

NAVA

14

79.3 ± 15.5

11 (78.6)

3.7 ± 2.8

17.4 ± 4.1

n/a

26.9 ± 10.7^&

n/a

n/a

Control

19

76.9 ± 9.3

13 (68.4)

4.3 ± 2.5

18.7 ± 5.0

n/a

27.1 ± 13.0^&

n/a

n/a

Ferreira 2017^a

NAVA

17

n/a

n/a

n/a

n/a

n/a

6.2 ± 2.8^*

6.0 (5.2, 8.0)

10.0 (8.0, 11.5)

Control

20

n/a

n/a

n/a

n/a

n/a

Fakher 2019

NAVA

15

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

Control

15

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

Hadfield 2020

NAVA

39

66.7 (13.9)

26 (66.7)

8.0 (6.0–8.0)

20.5 (6.0)

227.0 (82.0)

1.7 (1.1, 3.1)^#

8.9 (2.7)

n/a

Control

38

67.1 (12.9)

28 (73.7)

8.0 (5.5–10.0)

20.1 (6.1)

242.0 (83.0)

1.7 (0.7, 3.0)^#

8.9 (2.8)

n/a

Kacmarek 2020

NAVA

153

63.9 (15.4)

100 (65.4)

6.4 ± 3.1

16.1 ± 7

250 ± 87

2.4 ± 1.5^#

8 ± 2

n/a

Control

153

64.7 (14.1)

101 (66)

6.8 ± 3.3

16.4 ± 7.2

244 ± 88

2.0 ± 1.5^#

8 ± 3

n/a

Liu 2020

NAVA

47

80 (65, 80)

30 (64)

n/a

22 (16, 26)

279 (229,322)

5.0 (2.6, 7.6)^*

5 (5, 6)

8 (8, 10)

Control

52

75 (61, 80)

36 (69)

n/a

20 (17, 28)

271 (230, 349)

5.9 (3.0, 10.8)^*

5 (5, 6)

8 (7, 10)